Results 191 to 200 of about 53,615 (314)

Effect of the Arg16Gly β2‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study

open access: yesAllergy, Volume 81, Issue 3, Page 734-749, March 2026.
This study examines the association between the rs1042713 (Arg16Gly) polymorphism of the β2‐adrenergic receptor and the risk of severe eosinophilic asthma, as well as its influence on mepolizumab long‐term effectiveness and clinical remission. The Arg16 allele is associated with increased risk of severe disease and potentially diminished long‐term ...
Santi Nolasco   +38 more
wiley   +1 more source

Domestic and urban violence faced by community health workers: a multidimensional analysis in vulnerable territories in northeastern Brazil during and after the COVID-19 pandemic. [PDF]

open access: yesLancet Reg Health Am
Cardoso MR   +11 more
europepmc   +1 more source

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 5, Page 592-602, March 2026.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola   +4 more
wiley   +1 more source

Maternal and infant outcomes of planned mode of delivery in twin pregnancies: A systematic review and meta-analysis. [PDF]

open access: yesActa Obstet Gynecol Scand
Callado GY   +6 more
europepmc   +1 more source

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL‐321

open access: yesBritish Journal of Haematology, Volume 208, Issue 3, Page 926-936, March 2026.
Summary BRUIN CLL‐321 is the first prospective, randomized study conducted in covalent BTK inhibitor (cBTKi) pretreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients. In this heavily pretreated population, pirtobrutinib significantly improved progression‐free survival (PFS) compared to investigator's choice (IC) of ...
Shuhua Yi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy